Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
ACCESSWIRE
11 May 2021, 06:05 GMT+10
Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer
Announced encouraging preliminary data from a Phase 1b trial of gedatolisib plus Ibrance® and endocrine therapy for patients with ER+/HER2- metastatic breast cancer, in which gedatolisib showed a potentially differentiated safety and tolerability profile
Secured additional financing to strengthen cash position and provide funding for expanded clinical development activities
Entered into clinical trial collaboration agreements with leading cancer research centers, Novartis, Pfizer, and Puma to evaluate the efficacy of targeted therapies in patients selected with Celcuity s CELsignia Multi-Pathway Activity Test
United-states
American
Vicky-hahne
Celsignia-cdx
Robert-uhl
Brian-sullivan
Exchange-commission-on
Nasdaq
Novartis
Pfizer
American-association-for-cancer-research
Pfizer-inc